Alvin J. Siteman Cancer Center
Washington University Medical Campus
St. Louis, MO
Accepting patients
RALLY-MF
RALLY-MF: A Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and AnemiaA Phase 1b/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis and Anemia
- Monoclonal Antibody
- Hemojuvelin (HJV)
- Randomization
- Monotherapy
- Phase 1/2
- Has results
Not yet accepting
IRAK
Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)
- IRAK 4 Inhibitor
- IRAK 1 Inhibitor
- Phase 1/2
- Has results
Accepting patients
Collection of Tissue Samples for Cancer Research
Tissue Procurement Protocol for the Developmental Therapeutics Clinic, National Cancer Institute (NCI)
- Observational Trial
Accepting patients
BMS-986497 (ORM-6151)
Phase I Multicenter, Open-Label, First-in-Human Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double Combination With Azacitidine and in Triple Combination With Azacitidine and Venetoclax in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
- GSPT1 Degrader
- CD33
- Phase 1
Accepting patients
Interferon-γ With Donor Leukocyte Infusion
A Phase 2 Trial of Interferon-γ (IFN-γ) in Combination With Donor Leukocyte Infusion (DLI) to Treat Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) After Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
- Immunotherapy
- Donor Lymphocyte Infusion (DLI)
- Phase 2
Accepting patients
AK117/Placebo with Azacitidine
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes
- Monoclonal Antibody
- CD47
- Randomization
- Closed Label (Masked)
- Placebo
- Phase 2
Accepting patients
PedAL Screening
Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
- Phase 1/2
Accepting patients
ChromoSeq
A Prospective Study of Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS
- Genetic Sequencing
- Laboratory Assay
- Observational Trial
Accepting patients
ChromoSeq
A Prospective Study of Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
- Laboratory Assay
- Observational Trial
Accepting patients
MyeloMATCH Master Protocol
Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
- Genetic Sequencing
- Phase 2